Are Inhaled Vasodilators Useful in Acute Lung Injury and Acute Respiratory Distress Syndrome?
Authors: Siobal, Mark S; Hess, Dean R
Source: Respiratory Care, Volume 55, Number 2, February 2010 , pp. 144-161(18)
Publisher: The Journal Respiratory Care Company
Abstract:In patients with acute respiratory distress syndrome (ARDS), inhaled vasodilator can result in important physiologic benefits (eg, improved hypoxemia, lower pulmonary arterial pressure, and improved right-ventricular function and cardiac output) without systemic hemodynamic effects. Inhaled nitric oxide (INO) and aerosolized prostacyclins are currently the most frequently used inhaled vasodilators. Inhaled prostacyclins are as effective physiologically as INO and cost less. Randomized controlled trials of INO in the treatment of ARDS have shown short-term physiologic benefits, but no benefit in long-term outcomes. No outcome studies have been reported on the use of prostacyclin in patients with ARDS. There is no role for the routine use of inhaled vasodilators in patients with ARDS. Inhaled vasodilator as a rescue therapy for severe refractory hypoxemia in patients with ARDS may be reasonable, but is controversial.
Document Type: Research article
Publication date: 2010-02-01
- As of January 1, 2013, Respiratory Care content will no longer be hosted on ingentaconnect. Please contact the publisher at email@example.com for information on how to continue access to this title.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Clinical Practice Guidelines
- Past OPEN FORUM Abstracts
- ingentaconnect is not responsible for the content or availability of external websites